ETIOPATHOGENETIC THERAPY OF INFLAMMATORY DERMATOSES

Cover Page

Abstract


In chronic dermatoses significantly increases the colonization of skin by bacteria and fungi, which can have a negative impact on the course of inflammatory process. Cream Candiderm is a modern combined topical drug that has anti-inflammatory, antibacterial and antifungal activity.

The aim of the study was to assess the efficacy, safety and tolerability of the cream Candiderm in the treatment of patients with eczema and atopic dermatitis.

Material and methods. 37 patients with AD and 28 patients with eczema. Applied cream Candiderm 2 times a day, which was applied to the affected area of the skin. Before and on the 14 day of therapy was conducted bacteriological examination of the microflora of the skin rashes.

Results: at 14 days in patients with eczema remission was achieved in 17 (61 %) patients, significant improvement 6 (21 %), improvement in 4 (14 %), lack of effect in 1 (4 %); in patients with AD remission was observed in 23 (62 %) patients, significant improvement in 7 (19 %), and improvement in 5 (14 %), lack of effect in 2 (5 %).

Conclusions: high clinical efficacy of the cream of Candiderm allows recommending it for topical therapy of patients with eczema and atopic dermatitis.


About the authors

A. V. Samtsov

Military medical academy after S. M. Kirov, Ministry of Defence of the Russian Federation

Author for correspondence.
Email: avsamtsov@mail.ru

Russian Federation

Dr. Sci. (Medicine), Prof., Departmental Head, Department of Skin and Sexually Transmitted Diseases,

Academician Lebedev str., 6, Saint Petersburg, 194044

V. R. Khairutdinov

Military medical academy after S. M. Kirov, Ministry of Defence of the Russian Federation

Email: haric03@list.ru

Russian Federation

Dr. Sci. (Medicine), Ass. Prof., Department of Skin and Sexually Transmitted Diseases,

Academician Lebedev str., 6, Saint Petersburg, 194044

I. E. Belousova

Military medical academy after S. M. Kirov, Ministry of Defence of the Russian Federation

Email: irena.belousova@mail.ru

Russian Federation

Dr. Sci. (Medicine), Ass. Prof., Prof. of the Department of Skin and Sexually Transmitted Diseases,

Academician Lebedev str., 6, Saint Petersburg, 194044

References

  1. Chen Y. E., Tsao H. The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol. 2013;69(1):143–55.
  2. Grice E. A., Kong H. H., Renaud G., et al. A diversity profile of the human skin microbiota. Genome Res. 2008;18(7):1043–50.
  3. Jagielski T., Rup E., Ziołkowska A., et al. Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods. BMC Dermatol. 2014;14:3.
  4. Brodska P., Panzner P., Pizinger K., Schmid-Grendelmeier P. IgEmediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type. Dermatitis. 2014;25(3):120–6.
  5. Агафонова Е. Е., Дворянкова Н. В., Добриян З. Ф., Корсунская И. М. Терапия хронических дерматозов, осложненных Candida инфекцией. Terra medica. 2006;(1):34–35. [Agaphonova E. E., Dvoryankova N. V., Dobriyan Z. F., Korsunskaya I. M. Therapy of chronic dermatoses, complicated by Candida infection. Terra medica. 2006;(1):34–35.]
  6. Nguyen V., Huggins R. H., Lertsburapa T., et al. Cutaneous T-cell lymphoma and Staphylococcus aureus colonization. J Am Acad Dermatol. 2008;59(6):949–52.
  7. Haslund P., Bangsgaard N., Jarlov J. O., et al. Staphylococcus aureus and hand eczema severity. Br J Dermatol. 2009;161(4):772–7.
  8. Hanifin J. M., Rogge J. L. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol. 1977;113(10):1383–6.
  9. Williams R. E., Gibson A. G., Aitchison T. C., et al. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol. 1990;123(4):493–501.
  10. Leyden J. J., Marples R. R., Kligman A. M. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90(5):525–30.
  11. Kong H. H., Oh J., Deming C., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–9.
  12. Iwase T., Uehara Y., Shinji H., et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature. 2010;20:346–9.
  13. Iwamoto K., Moriwaki M., Niitsu Y., et al. Staphylococcus aureus from atopic dermatitis skin alters cytokine production triggered by monocyte-derived Langerhans cell. J Dermatol Sci. 2017 Aug 5:S0923- 1811(17)30502-9.
  14. Tauber V. U., Amin M., Fuchs P., et al. Comparative studies in man on the percutaneous absorption of diflucortolone valerate, betamethasone-17-valerate, beclomethasone dipropionate and fluocinolone acetonide. Arzneimittelforschung. 1976;26(7b):1492–5.
  15. Матушевская Е. В., Масюкова С. А. Топические комбинированные кортикостероидные препараты в лечении атопического дерматита. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2009;(2):14–19. [Matushevskaya E. V., Masyukova S. A. Topical combined corticosteroids in the treatment of atopic dermatitis. Modern problems of dermatovenereology, immunology and medical cosmetology. 2009;(2):14–19.]
  16. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis, the SCORAD index. Dermatology 1993;186:23–31.
  17. Hanifin J., Thurston M., Omoto M., et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental Dermatology 2001;10(1):11–8.
  18. Gift A. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabilitation Nursing. 1989;14:313–35.
  19. Roberts J.K., Moore C.D., Ward R.M., Yost G.S., Reilly C.A. Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308–16.
  20. Хэбиф Т. П. Кожные болезни: диагностика и лечение. М.: МЕД пресс-информ, 2008. [Habif T. P. Skin diseases: diagnosis and treatment. Moscow: MED Press Information, 2008.]
  21. Соколова Т. В., Гладько В. В., Флакс Г. А., Малярчук А. П., Сафонова Л. А. Микробная экзема как инфекционно-зависимый дерматоз в практике врача дерматовенеролога. Учебное пособие для врачей. М.: Ваш формат, 2017:60. [Sokolova T. V., Gladko V. V., Flaks G. A., Malyarchuk A. P., Safonova L. A. Microbial eczema as an infectious-dependent dermatosis in the practice of a dermatovenereologist. Textbook for doctors. Moscow: YOUR FORMAT, 2017:60.]
  22. Агафонова Е. Е., Дворянкова Н. В., Добриян З. Ф., Корсунская И. М. Терапия хронических дерматозов, осложненных Candida инфекцией. М.: TerraMedica, 2006. [Agafonova E. E., Dvoryankova N. V., Dobriyan Z. F., Korsunskaya I. Therapy of chronic dermatoses complicated by Candida infection. Moscow: TerraMedica, 2006.]
  23. Patel R. S. et al. Предварительные результаты пилотного исследования по изучению возможности измерения кортизола в слюне для выявления скрытого подавления надпочечниково, вторичного по отношению к применению назальных стероидов. Clin Otolaryngol Allied Sci. 2001 Jun;26(3):231–4. [Patel R. S. et al. Preliminary results of a pilot study aimed at investigating the possibility of measuring cortisol in saliva to detect latent suppression of the adrenal glands, secondary to the use of nasal steroids. Clin Otolaryngol Allied Sci. 2001 Jun; 26 (3): 231–4.]

Statistics

Views

Abstract - 376

PDF (Russian) - 122

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies